Principal Investigators

    Anders Sandberg


    Alzinova AB

    Contact information of lead PI



    Title of project or programme

    Immunological and histochemical assessment of an Alzheimer´s vaccine

    Source of funding information


    Total sum awarded (Euro)

    € 54,407

    Start date of award


    Total duration of award in years



    Research Abstract

    Alzinova is developing an Alzheimer´s disease vaccine, ALZ-101. This vaccine is a therapeutic vaccine, and is designed to arrest disease progression and prevent neurodegeneration in the brain. The vaccine is capable of specifically targeting the endogenous substance that causes disease – a feat made possible by a proprietary technology that stabilizes the antigen. In consequence, it is only this stable structure that is presented to the immune system, thus inducing B-cells to produce antibodies specific for it. The strength of this comapny is the unique capability of actually targeting the ´needles in the haystack´ and not just the ´straws´. This unique specificity is expected to translate into high clinical efficacy and an acceptable safety profile.The vaccine has been evaluated in mice with good results: Both naive mice and a transgenic model of Alzheimer´s disease support the concept and the proposed mechanism of action for this vaccine. Before commencing preclinical development, the vaccine is set to be evaluated immunologically in a separate species, as well as safety assessed by histochemical analysis on human tissue samples. These activities aim to verify the animal species as a model system for the full preclinical development project, as well as to establish that the immune response is specific for the target and not other tissue components.

    Further information available at:

Types: Investments < €500k
Member States: Sweden
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF